

Title (en)
PHARMACEUTICAL COMPOSITION

Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG

Title (fr)
COMPOSITION PHARMACEUTIQUE

Publication
EP 0969842 A1 20000112 (EN)

Application
EP 98912622 A 19980324

Priority
• GB 9800885 W 19980324
• GB 9706089 A 19970324

Abstract (en)
[origin: WO9842344A1] This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT₁ agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT₁ agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.

IPC 1-7
A61K 31/505; A61K 31/445; A61K 31/435; A61K 31/495; A61K 9/00

IPC 8 full level
A61K 9/00 (2006.01); **A61K 9/20** (2006.01); **A61K 31/4045** (2006.01); **A61K 31/438** (2006.01); **A61K 31/45** (2006.01); **A61K 31/496** (2006.01); **A61K 31/506** (2006.01); **A61K 31/535** (2006.01); **A61K 45/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01); **A61P 37/02** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP)
A61K 9/0056 (2013.01); **A61K 31/438** (2013.01); **A61K 31/45** (2013.01); **A61K 31/496** (2013.01); **A61K 31/506** (2013.01); **A61P 25/00** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 25/30** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)
See references of WO 9842344A1

Citation (third parties)
Third party :
• EP 0486666 B1 19970813 - ZENECA LTD [GB]
• YUNXIA BI; ET AL: "PREPARATION AND EVALUATION OF A COMPRESSED TABLET RAPIDLY DISINTEGRATING IN THE ORAL CAVITY", CHEM. PHARM. BULL., vol. 44, no. 11, 1996, pages 2121 - 2127, XP000636227
• UNITED STATES PHARMACOPEIAL CONVENTION: "THE UNITED STATES PHARMACOPEIA. THE NATIONAL FORMULARY", 2006, UNITED STATES PHARMACOPEIAL CONVENTION, US, ISBN: 1-889788-47-3, pages: 629, XP003019579
• DOENICKE A. ET AL.: "Effective improvement of symptoms in patients with acute migraine by GR43175 administered in dispersible tablets", CEPHALALGIA, vol. 9, no. SUPPL.9, 1989, pages 89 - 92, XP008094994
• C.J. THOMSON (STUDY COORDINATOR): "A study to compare oral sumatriptan with oral aspirin plus Oral Metoclopramide in the Acute Treatment of Migraine", EUR NEUROL, vol. 32, no. 3, 1992, pages 177 - 184, XP008095009
• J. P. PATTEN AND THE ORAL SUMATRIPTAN DOSE-DEFINING STUDY GROUP: "Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study", J NEUROL, vol. 238, no. SUPPL.1, February 1991 (1991-02-01), pages 1432 - 1459, XP008094995
• LACEY L.F. ET AL.: "Single dose pharmacokinetics of sumatriptan in healthy volunteers", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 6, February 1995 (1995-02-01), pages 543 - 548, XP008094998

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9842344 A1 19981001; AU 6740298 A 19981020; EP 0969842 A1 20000112; GB 9706089 D0 19970514; JP 2001518925 A 20011016

DOCDB simple family (application)
GB 9800885 W 19980324; AU 6740298 A 19980324; EP 98912622 A 19980324; GB 9706089 A 19970324; JP 54523598 A 19980324